Published in Liver Transpl on October 01, 2001
Role of living liver donation in the United Kingdom. BMJ (2003) 1.82
Right living donor liver transplantation: an option for adult patients: single institution experience with 74 patients. Ann Surg (2003) 1.31
Living donor liver transplantation. HPB (Oxford) (2006) 0.82
Historical perspective of living donor liver transplantation. World J Gastroenterol (2008) 0.79
Live liver donors' risk thresholds: risking a life to save a life. HPB (Oxford) (2013) 0.77
The outcomes of pediatric liver retransplantation from a living donor: a 17-year single-center experience. Surg Today (2017) 0.75
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76
The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89
Rapid modification of bacterial artificial chromosomes by ET-recombination. Nucleic Acids Res (1999) 6.85
An alternative strategy for studying adverse events in medical care. Lancet (1997) 5.98
Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol (1995) 5.86
Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01
Sounding Boards. Confidentiality in medicine--a decrepit concept. N Engl J Med (1982) 5.00
Intestinal transplantation in composite visceral grafts or alone. Ann Surg (1992) 4.96
The rise and fall of the futility movement. N Engl J Med (2000) 4.88
DNA cloning by homologous recombination in Escherichia coli. Nat Biotechnol (2000) 4.75
Effects of organizational change in the medical intensive care unit of a teaching hospital: a comparison of 'open' and 'closed' formats. JAMA (1996) 4.71
Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32
Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18
Basic curricular goals in medical ethics. N Engl J Med (1985) 4.03
Liver transplantation in the United States, 1999-2008. Am J Transplant (2010) 3.92
Is tocolytic magnesium sulphate associated with increased total paediatric mortality? Lancet (1997) 3.77
Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63
Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40
Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34
Community hospital ethics consultation: evaluation and comparison with a university hospital service. Am J Med (1992) 3.30
Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29
Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26
Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18
The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14
Beyond autonomy--physicians' refusal to use life-prolonging extracorporeal membrane oxygenation. N Engl J Med (1993) 2.96
Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91
Functional characterization of infiltrating T lymphocytes in human hepatic allografts. Hum Immunol (1986) 2.84
Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. Transplant Proc (1993) 2.81
Cadaveric small bowel and small bowel-liver transplantation in humans. Transplantation (1992) 2.75
Management of intestinal transplantation in humans. Transplant Proc (1992) 2.62
Transplantation of liver grafts from living donors into adults--too much, too soon. N Engl J Med (2001) 2.61
Should alcoholics compete equally for liver transplantation? JAMA (1991) 2.61
Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60
What are the goals of ethics consultation? A consensus statement. J Clin Ethics (1996) 2.59
Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation (1990) 2.59
Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59
The prediction of risk of recurrence and time to recurrence of hepatocellular carcinoma after orthotopic liver transplantation: a pilot study. Hepatology (1997) 2.57
Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst (1993) 2.57
FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation (1994) 2.50
Pregnancy after liver transplantation under tacrolimus. Transplantation (1997) 2.50
Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc (1990) 2.48
Living donor renal transplantation using alemtuzumab induction and tacrolimus monotherapy. Am J Transplant (2006) 2.48
Ethics of liver transplantation with living donors. N Engl J Med (1989) 2.47
Prioritization and organ distribution for liver transplantation. JAMA (1994) 2.38
In vitro antimicrobial production of beta-lactamases, aminoglycoside-modifying enzymes, and chloramphenicol acetyltransferase by and susceptibility of clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother (1993) 2.34
The antibody crossmatch in liver transplantation. Surgery (1986) 2.33
The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg (1994) 2.32
Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg (1998) 2.31
Differential survival of hamster-to-rat liver and cardiac xenografts under FK 506 immunosuppression. Transplant Proc (1991) 2.28
Beyond advance directives--health care surrogate laws. N Engl J Med (1992) 2.26
Assessment of five-year experience with abdominal organ cluster transplantation. J Am Coll Surg (1995) 2.25
Searching for moral certainty in medicine: a proposal for a new model of the doctor-patient encounter. Bull N Y Acad Med (1981) 2.25
Should HLA mismatch acceptability for sensitized transplant candidates be determined at the high-resolution rather than the antigen level? Am J Transplant (2015) 2.24
Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system. J Am Coll Surg (1999) 2.22
Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant (2006) 2.22
Three years clinical experience with intestinal transplantation. J Am Coll Surg (1994) 2.20
Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation (1992) 2.20
Mutation in the gyrA gene of quinolone-resistant clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother (1995) 2.19
Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology (1999) 2.19
Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg (1997) 2.16
Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium. Clin Infect Dis (1996) 2.12
Paradoxes in cancer patients' advance care planning. J Palliat Med (2000) 2.11
One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. Transplant Proc (1991) 2.10
Shifts in clostridia, bacteroides and immunoglobulin-coating fecal bacteria associated with weight loss in obese adolescents. Int J Obes (Lond) (2008) 2.09
A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation (1995) 2.09
The side effects of FK 506 in humans. Transplant Proc (1990) 2.08
Randomised trialomania? The multicentre liver transplant trials of tacrolimus. Lancet (1995) 2.04
Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N Engl J Med (1997) 2.03
Elective surgical patients as living organ donors: a clinical and ethical innovation. Am J Transplant (2009) 2.02
Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg (1998) 1.99
Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. Transplantation (1991) 1.95
A legacy of Osler. Teaching clinical ethics at the bedside. JAMA (1978) 1.95
Successful hamster-to-rat liver xenotransplantation under FK506 immunosuppression induces unresponsiveness to hamster heart and skin. Transplantation (1993) 1.94
FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood. Lancet (1990) 1.94
Point mutation of bacterial artificial chromosomes by ET recombination. EMBO Rep (2000) 1.90
Acute liver failure: clinical features, outcome analysis, and applicability of prognostic criteria. Liver Transpl (2000) 1.88
Growth of donor-derived dendritic cells from the bone marrow of murine liver allograft recipients in response to granulocyte/macrophage colony-stimulating factor. J Exp Med (1995) 1.88
Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients. Transplantation (1996) 1.86
Clinical ethics consultation: Godsend or "God squad"? Am J Med (1988) 1.86
Reduced-size orthotopic liver transplantation: use in the management of children with chronic liver disease. Hepatology (1989) 1.84
Experience with liver and kidney allografts from non-heart-beating donors. Transplantation (1995) 1.83
Orthotopic liver transplantation in the mouse. Transplantation (1991) 1.82
Apoptosis within spontaneously accepted mouse liver allografts: evidence for deletion of cytotoxic T cells and implications for tolerance induction. J Immunol (1997) 1.81
An ethics consultation service in a teaching hospital. Utilization and evaluation. JAMA (1988) 1.80
Obesity and immune function relationships. Obes Rev (2001) 1.80
Pathologic observations in human allograft recipients treated with FK 506. Transplant Proc (1990) 1.80
Early events in liver allograft rejection. Delineation of sites of simultaneous intragraft and recipient lymphoid tissue sensitization. Am J Pathol (1991) 1.78
Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease. Br J Surg (2009) 1.78
Euthanasia--a critique. N Engl J Med (1990) 1.77
Use of FK 506 in pediatric patients. Transplant Proc (1991) 1.77
High level of physical activity preserves the cardioprotective effect of preinfarction angina in elderly patients. J Am Coll Cardiol (2001) 1.75
The illusion of futility in clinical practice. Am J Med (1989) 1.73
Randomized trial of FK 506/prednisone vs FK 506/azathioprine/prednisone after renal transplantation: preliminary report. Transplant Proc (1993) 1.72
'Doctors must not kill'. JAMA (1988) 1.71
Transplantation. JAMA (1990) 1.71
Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation (1999) 1.70
Ethical issues in growth hormone therapy. JAMA (1989) 1.69
Life-sustaining treatment. A prospective study of patients with DNR orders in a teaching hospital. Arch Intern Med (1988) 1.68
Frailty predicts long-term mortality in elderly subjects with chronic heart failure. Eur J Clin Invest (2005) 1.68